Introduction
============

The 2-amino-5-arylidene-5*H*-thiazol-4-ones and their 5-arylidene rhodanine precursors are a class of five-membered heterocyclic rings (FMHRs) considered as "privileged scaffolds" in the medicinal chemistry community \[[@b1-scipharm.2012.80.825]\]. Considerable work has been published over decades about their chemistry and biology. A number of compounds containing the 2-amino-5-arylidenethiazol-4(5*H*)-one moiety have been shown to exhibit anti-inflammatory \[[@b2-scipharm.2012.80.825]\], antimicrobial \[[@b3-scipharm.2012.80.825]\], and antitumor \[[@b4-scipharm.2012.80.825]\] effects. Among these compounds, Darbufelone® **A**\[[@b5-scipharm.2012.80.825]\] ([Figure 1](#f1-scipharm.2012.80.825){ref-type="fig"}) is orally active in animal models of inflammation \[[@b6-scipharm.2012.80.825]\] and DBPT **B** is under clinical trials for colon cancer \[[@b7-scipharm.2012.80.825]\]. 5-Arylidene rhodanines have also proven to be attractive for the discovery of new candidates. A series of rhodanine-based hits **C** ([Figure 1](#f1-scipharm.2012.80.825){ref-type="fig"}) were found as potent and selective inhibitors of the "atypical" dual-specificity phosphatase (DSP) family member-JNK-stimulating phophatase-1 (JSP-1). Compounds of this class may be useful for the treatment of inflammatory and proliferative disorders \[[@b8-scipharm.2012.80.825]\]. As the last example, epalrestat **D** reduced the symptoms of diabetic neuropathy \[[@b9-scipharm.2012.80.825]\].

Protein kinases are the enzymes which control the phosphorylation of protein in cellular life \[[@b10-scipharm.2012.80.825]\] which is frequently deregulated in human diseases. For the pharmaceutical industry, the protein kinases represent interesting targets for new therapeutic agents \[[@b11-scipharm.2012.80.825]\] and this interest was boosted by the approval of the first marketed inhibitor Gleevec™ used in myeloid leukemia \[[@b12-scipharm.2012.80.825]\]. Due to the biological activity associated with the 2-amino-thiazolidinone moiety, we decided in this paper to explore the synthesis of *N,N'*-bis(5-arylidene-4-oxo-4,5-dihydrothiazolidin-2-yl)diamines derived from piperazine or 1,4-bis(3-aminopropyl)piperazine as linkers, and to study their effects on cells and protein kinases.

Results and Discussion
======================

Chemistry
---------

The strategy used for the synthesis of the symmetric derivatives **5** is outlined in [Scheme 1](#f2-scipharm.2012.80.825){ref-type="fig"}. The reactions have been realized under microwave irradiation \[[@b13-scipharm.2012.80.825]\]. The main benefits of microwave irradiation technology are the significant rate-enhancements and sometimes elevated product yields enabling the rapid synthesis of molecules of potential value in medicinal chemistry \[[@b14-scipharm.2012.80.825]\]. The synthesis started by the solution-phase Knoevenagel condensation of aryl aldehydes **2** and commercial rhodanine **1a**. The expected compounds **3a--c** were prepared in yields ranging from 65 to 88% with a reaction time of 10 min. under microwave irradiation (MWI) at 65°C in the presence of sodium acetate. In a similar approach, the 5-arylidene rhodanine propanoic derivatives **3d--g** were easily synthesized using solvent-less reaction conditions under microwave irradiation (130°C, 10 min.). The geometric double bond of **3** was attributed as being *Z* by the shielding effect of the carbonyl group C-4 on the olefinic proton H-5 (δ 7.5 ppm) in the ^1^H NMR spectra.

Transformation of 5-arylidene rhodanine **3** into 2-amino-5-arylidene-5*H*-thiazol-4-one after addition of a primary amine \[[@b15-scipharm.2012.80.825]\] usually involves activation of the C=S bond of rhodanine via the thioether intermediate that subsequently undergoes a thioalkyl/nitrogen displacement. In order to be able to carry out such sulfur/nitrogen displacement in a faster and more efficient way -- avoiding the preparation of the thioether intermediate -- we examined the influence of microwave irradiation on the reaction between compound **3** and the symmetric diamino linkers **4a,b**. The experiments revealed that optimal reaction conditions were obtained at 80--120°C after 30 minutes. It is noteworthy that sulfur/nitrogen displacement reactions at 120°C under microwave irradiation have been realized in solution with hexane to avoid decomposition of compound **5**. The desired compounds **5a--e** were prepared in poor to moderate yields (13--26%) and their structures were substantiated by ^1^H, ^13^C NMR, and HRMS analyses and only the more thermo-dynamically stable *Z-*isomers were obtained.

Biology
-------

To evaluate the potency of the compounds **3a--c**, **5a,** and **5c** for their *in vitro* antiproliferative activities, we used six representative tumor cell lines of liver (Huh7), colon (Caco2, HCT 116), breast (MDA-MB 231), prostate (PC3), lung (NCI), and one normal cell line (fibroblats) and measured survival. Results are reported in [Table 1](#t1-scipharm-2012-80-825){ref-type="table"}. The 5-arylidene rhodanines **3a--c** and two compounds **5a** and **5c** showed measurable, albeit very poor, cytotoxic activity. No clear tendency for higher activity of these compounds can be deduced from these results. Since the log P values of all tested compounds are in the same range, influences of lipophilicity on cytotoxic activity cannot be deduced as well.

The kinase inhibitory potencies of compounds **3a--c** and **5d** were evaluated as IC~50~ values towards six protein kinases (CDK5/p25, GSK3α/β, DYRK1A, DYRK2, CLK1 and CLK2) and the results are reported in [Table 2](#t2-scipharm-2012-80-825){ref-type="table"}. The 5-arylidene rhodanines **3a,b** appeared to be inactive towards these six protein kinases, but interesting results were obtained with compounds **5d** and **3c**. The 1,4-bis\[(5*Z*)-5-(4-methoxybenzylidene)methylene-4-oxo-4,5-dihydrothiazol-2-yl\]piperazine **5b** and the 5-arylidene rhodanine **3c** are very active on DYRK1A \[[@b16-scipharm.2012.80.825]\] and a noteworthy IC~50~ = 41 nM was measured for **5b**. The compound **5d** has also shown submicromolar inhibition potencies towards DYRK2 (IC~50~ = 0.6 μM) and CLK1 (IC~50~ = 0.5 μM). Regarding these results, the potential of the (5*Z*) 5-arylidene-4-oxo-4,5-dihydro-thiazolidine-2-yl moiety appended on 1,4-bis(3-aminopropyl)piperazine **4b** as a linker could be highly interesting in the development of a new class of inhibitors of DYRK1A kinase which is known to be involved in Alzheimer's disease/Down syndrome \[[@b17-scipharm.2012.80.825]\].

Conclusion
==========

In conclusion, we worked out a short and practical synthesis under microwave irradiation of *N,N'*-(5-arylidene-4-oxo-4,5-dihydrothiazolidin-2-yl)diamines **5a--e** derived from piperazine **4a**\[[@b18-scipharm.2012.80.825], [@b19-scipharm.2012.80.825]\] and 1,4-bis(3-aminopropyl)piperazine **4b**. The *in vitro* anti-proliferative activities are extremely weak and this could be due to a lower cellular penetration of compounds **3** and **5** or a lower interaction with the cellular targets. Surprisingly, the compound **5d** has shown nanomolar inhibition potency towards DYRK1A and this interesting inhibition led us to expand our efforts in the synthesis of diversely disubstituted *N,N'*-bispiperazine derivatives with the 5-arylidene thiazolidinone moiety as new potential inhibitors of this kinase. Work is in progress to gain deeper insight into the structure-activity relationships (SAR) of this new interesting class of diamines.

Experimental
============

General
-------

Elemental analysis: Flash EA1112 CHN/O Thermo Electron; HRMS (MS/MS ZABSpec Tof Micromass, EBE TOF geometry, IP 8 eV); NMR: BRUKER AC 300P (^1^H: 300 MHz, ^13^C: 75 MHz); melting points: Leica System Kofler VMHB Melting Point apparatus (not corrected); microwave reactor: Monowave 300 Anton-Paar (850 W), monowave software package.

General procedure I: Preparation of 5-arylidene-2-thioxo-thiazolidine-4-one 3a--c under microwave irradiation
-------------------------------------------------------------------------------------------------------------

A mixture of rhodanine **1a** (1 g, 7.5 mmol), aldehyde **2** (8.95--9 mmol), sodium acetate (1.85 g, 22.55 mmol), and methanol (5 ml) was placed in a borosilicate glass vial (10 ml) with a Teflon® magnetic stir bar and sealed with a snap cap. The glass tube was then introduced into the Monowave 300 Anton-Paar microwave cavity (P = 850 Watt) and the stirred mixture was irradiated at 65°C (with a power of 10 Watt) for 30 min. After microwave dielectric heating, the crude reaction mixture was allowed to cool down to room temperature, and then was filtered on a Buchner funnel and the insoluble compound **3** was washed with methanol (2x5 ml). The crude compound **3** was purified by recrystallization from methanol and further dried under high vacuum (10^−2^ Torr) for 1 hour, which gave the desired compound **3** as a powder.

General procedure II: Preparation of 3-(5-arylidene-4-oxo-2-thioxo-thiazolidine-3-yl)propanoic acid 3d--g under solvent-free microwave irradiation
--------------------------------------------------------------------------------------------------------------------------------------------------

A mixture of rhodanine **1b** (0.5 g, 2.44 mmol) and aldehyde **2** (2.44 mmol) was placed in a borosilicate glass vial (10 ml) with a Teflon® magnetic stir bar and sealed with a snap cap. The glass tube was then introduced into the Monowave 300 Anton-Paar microwave cavity (P = 850 Watt) and the stirred mixture was irradiated at 130°C for 10 min. After microwave dielectric heating, the crude reaction mixture was allowed to cool down to room temperature and 5 ml of a mixture of ethanol/hexane (1:1) were added directly to the glass vial. The resulting precipitated product **3** was filtered on a Buchner funnel and the insoluble compound **3** was washed with the same mixture (2x5 ml). The crude compound **3** was further dried under high vacuum (10^−2^ Torr) for 1 hour, which gave the desired compound **3** as a powder.

General procedure III: Synthesis of N,N'-bis(5-arylidene-4-oxo-4,5-dihydro-thiazolidine-2-yl)piperazine derivatives 5a--e under microwave irradiation
-----------------------------------------------------------------------------------------------------------------------------------------------------

A mixture of 5-arylidene-2-thioxo-thiazolidine-4-one **3** (4 mmol), piperazine **4a** (172 mg, 2 mmol) or 1,4-bis(3-aminopropyl)piperazine **4b** (400 mg, 2 mmol) was placed in a borosilicate glass vial (10 ml) with a Teflon® magnetic stir bar and sealed with a snap cap. The glass tube was then introduced into the Monowave 300 Anton-Paar microwave cavity (P = 850 Watt) and the stirred mixture was irradiated at 80--120°C (with a power of 5--200 Watt) for 30 min. After microwave dielectric heating, the crude reaction mixture was allowed to cool down to room temperature and 10 ml of cooled ethanol (4°C) were added directly in the glass vial. The resulting precipitated product **5** was filtered off, washed with 2 × 5 ml of ethanol and dried under high vacuum (10^−2^ Torr) at room temperature for 1 hour. After ^1^H NMR analysis, the product **5** was purified by recrystallization from methanol, which gave the desired compound **3** as a powder.

(5Z)-5-Benzylidene-2-thioxo-1,3-thiazolidin-4-one (3a)
------------------------------------------------------

Prepared following General procedure I from benzaldehyde **2a** (0.95 g, 8.95 mmol) to give 1.08 g (65%) as an orange powder. Mp = 208--210°C. ^1^H NMR (300 MHz, DMSO-*d*~6~) δ (ppm) = 7.44--7.55 (m, 5H, Ar), 7.57 (s, 1H, =CH), 13.12 (br s, 1H, NH). ^13^C NMR (75 MHz, DMSO-*d*~6~) δ (ppm) = 126.88 (C-1), 129.20 (C-2), 130.30 (C-3), 130.37 (C-4), 130.45 (C=, C-5), 133.22 (=CH), 171.28 (C=S, C-2); 196,64 (C=O, C-4). HRMS, *m/z* = 243.9868 found (calculated for C~10~H~7~NONaS~2~, \[M+Na\]^+^ requires 243.9867). Anal. Calcd. for C~10~H~7~NOS~2~: C, 54.27; H, 3.19. Found: C, 54.23; H, 3.16.

(5Z)-5-(4-Methoxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one (3b)
-----------------------------------------------------------------

Prepared following General procedure I from 4-methoxybenzaldehyde **2b** (1.23 g, 9 mmol) to give 1.36 g (74%) as an orange powder. Mp = 250--252°C. ^1^H NMR (300 MHz, DMSO-*d*~6~) δ (ppm) = 3.82 (s, 3H, OCH~3~), 7.10 (d, *J* = 8.8Hz, 2H, H-3, Ar), 7.55 (d, *J* = 9.1 Hz, 2H, H-2, Ar), 7.57 (s, 1H; =CH), 13.76 (br s, 1H, NH). ^13^C NMR (75 MHz, DMSO-*d*~6~) δ (ppm) = 55.45 (OCH~3~), 114.92 (C-3'), 124.90 (C=, C-5), 126.02 (C-1'), 129.71 (=CH), 132.28 (C-2'), 160.82 (C-4'), 173.024 (C=S, C-2), 197.25 (C=O, C-4). HRMS, *m/z* = 295.9792 found (calculated for C~11~H~9~NO~2~Na~2~S~2~, \[M-H+2Na\]^+^ requires 295.9792). Anal. Calcd. for C~11~H~9~NO~2~S~2~: C, 52.57; H, 3.61. Found: C, 52.65; H, 3.67.

(5Z)-5-(1,3-Benzodioxol-5-ylmethylidene)-2-thioxo-1,3-thiazolidin-4-one (3c)
----------------------------------------------------------------------------

Prepared following General procedure I from piperonaldehyde **2c** (1.35 g, 9 mmol) to give 1.74 g (88%) as an orange powder. Mp \> 260°C. ^1^H NMR (300 MHz, DMSO-*d*~6~) δ (ppm) = 6.13 (s, 2H; OCH~2~O), 7.11--7.45 (m, 3H; H-5', H-6', Ar), 7.52 (s, 1H, =CH), 7.55 (s, 1H, H-2'; Ar), 13.74 (br s, 1H, NH). ^13^C NMR (75 MHz, DMSO-*d*~6~) δ (ppm) = 102.10 (OCH~2~O), 109.26 (C=, C-5), 109.45 (C-6'), 123.02 (C-1'), 126.65 (C-5'), 127.16 (=CH), 131.81 (C-2'), 148.27 (C-4'), 149.60 (C-3'), 169.58 (C=S, C-2), 195.51 (C=O, C-4). HRMS, *m/z* = 287.9765 found (calculated for C~11~H~7~NO~3~NaS~2~, \[M+Na\]^+^ requires 287.9765). Anal. Calcd. for C~11~H~7~NO~3~S~2~: C, 49.80; H, 2.66. Found: C, 49.91; H, 2.69.

3-\[(5Z)-5-Benzylidene-4-oxo-2-thioxo-1,3-thiazolidin-3-yl\]propanoic acid (3d)
-------------------------------------------------------------------------------

Prepared following General procedure II from benzaldehyde **2a** (0.256 g, 2.44 mmol) to give **3d** in 60% yield as a brown powder. Mp = 224--226°C. ^1^H NMR (300 MHz, DMSO-*d*~6~) δ (ppm) = 2.33 (m, 2H, CH~2~), 4.15 (m, 2H, CH~2~), 7.51--7.65 (m, 5H, H-2, H-3, H-4, Ar), 7.80 (s, 1H, =CH), 13.16 (br s, 1H, OH). ^13^C NMR (75 MHz, DMSO-*d*~6~) δ (ppm) = 33.30 (CH~2~), 41.78 (CH~2~), 122.6 (C=, C-5), 129.46 (C-2'), 130.57 (C-3'), 130.84 (C-4'), 132.63 (=CH), 133.02 (C-1), 166.76 (C=O, C-4), 171.94 ([C]{.ul}O~2~H), 193.15 (C=S, C-2). HRMS, *m/z* = 337.9904 found (calculated for C~13~H~10~NO~3~Na~2~S~2~, \[M-H+2Na\]^+^ requires 337.9898).

3-\[(5Z)-5-(4-Methoxybenzylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl\]propanoic acid (3e)
------------------------------------------------------------------------------------------

Prepared following General procedure II from 4-methoxybenzaldehyde **2b** (0.332 g, 2.44 mmol) to give **3e** in 60% as a brown powder. Mp \> 260°C. ^1^H NMR (300 MHz, DMSO-*d*~6~) δ (ppm) = 2.24 (t, 2H, J = 8.2 Hz, CH~2~), 3.83 (s, 3H, OCH~3~), 4.12 (t, 2H, J = 8.2 Hz, CH~2~), 7.10 (d, 2H, J = 8. 8 Hz, H-3, Ar), 7.64 (d, 2H, J = 8.8 Hz, H-2, Ar), 7.86 (s, 1H, =CH), 13.26 (br s, 1H, OH). ^13^C NMR (75 MHz, DMSO-*d*~6~) δ (ppm) = 34.11 (CH~2~), 42.20 (CH~2~), 55.56 (OCH~3~), 115.11 (C-3'), 119.26 (C=, C-5), 125.58 (C-1'); 129.90 (=CH), 132.84 (C-2'), 161.41 (C-4'), 166.86 (C=O, C-4), 171.98 (CO~2~H), 192.86 (C=S, C-2). HRMS, *m/z* = 346.0185 found (calculated for C~14~H~13~NO~4~NaS~2~, \[M+Na\]^+^ requires 346.0184).

3-\[(5Z)-5-(1,3-Benzodioxol-5-ylmethylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl\]propanoic acid (3f)
-----------------------------------------------------------------------------------------------------

Prepared following General procedure II from piperonal **2c** (0.366 g, 2.44 mmol) to give **3f** in 63% as a brown powder. Mp = 220--224°C. ^1^H NMR (300 MHz, DMSO-*d*~6~) δ (ppm) = 2.61 (t, 2H, J = 3.9 Hz, CH~2~), 4.21 (t, 2H, J = 4.7 Hz, CH~2~), 6.15 (s, 2H, OCH~2~O), 7.09--7.23 (m, 3H, H-2, H-5, H-6, Ar), 7.74 (s, 1H, =CH), 12.50 (br s, 1H, OH). ^13^C NMR (75 MHz, DMSO-*d*~6~) δ (ppm) = 30.74 (CH~2~), 40.30 (CH~2~), 102.21 (OCH~2~O), 109.35 (C-2'), 109.61 (C-5'), 119.71 (C=, C-5), 126.98 (C-6'), 127.14 (C-1'), 133.21 (=CH), 148.35 (C-4'), 149.88 (C-3'), 166.67 (C=O, C-4), 171.72 (CO~2~H), 192.97 (C=S, C-2). HRMS, *m/z* = 346.0185 found (calculated for C~14~H~13~NO~4~NaS~2~, \[M+Na\]^+^ requires 346.0184).

3-\[(5Z)-5-(2,3-Dihydro-1,4-benzodioxin-6-ylmethylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl\]propanoic acid (3g)
-----------------------------------------------------------------------------------------------------------------

Prepared following General procedure II from 1,4-benzodioxane-6-carboxaldehyde (**2d**) (0.401 g, 2.44 mmol) to give **3g** in 54% yield as a brown powder. Mp = 226--228°C. ^1^H NMR (300 MHz, DMSO-*d*~6~) δ (ppm) = 2.55 (t, 2H, J = 7.3 Hz, CH~2~), 4.18 (t, 2H, J = 7.4 Hz, CH~2~), 4.30 (m, 4H, OCH~2~CH~2~O), 7.02 (d, 1H, J = 8.6 Hz, H-5, Ar), 7.12 (d, 1H, J = 2.2 Hz, H-6, Ar), 7.15 (s, 1H, H-2, Ar), 7.70 (s, 1H; =CH), 12.46 (br s, 1H, OH). ^13^C NMR (75 MHz, DMSO-*d*~6~) δ (ppm) = 31.30 (CH~2~), 40.30 (CH~2~), 64.01 (OCH~2~CH~2~O), 118.22 (C-2'), 119.47 (C-5'), 119.79 (C=, C-5), 124.46 (C-6'), 126.31 (C-1'), 132.96 (=CH), 143.82 (C-4'), 146.25 (C-3'); 166.67 (C=O, C-4), 171.80 (CO~2~H), 192.93 (C=S, C-2). HRMS, *m/z* = 374.0138 found (calculated for C~15~H~13~NO~5~NaS~2~, \[M+Na\]^+^ requires 374.0133).

(5Z,5'Z)-2,2'-(Piperazine-1,4-diyl)bis(5-benzylidene-1,3-thiazol-4(5H)-one) (1,4-Bis\[(5Z)-5-benzylidene-4-oxo-4,5-dihydro-1,3-thiazol-2-yl\]piperazine, 5a)
------------------------------------------------------------------------------------------------------------------------------------------------------------

Prepared following General procedure III from 5-benzylidene-2-thioxo-thiazolidin-4-one (**3a**) (885 mg, 4 mmol) and piperazine **4a** (172 mg, 2 mmol) in hexane (2 ml) at 120°C to give **5a** in 13% yield as a brown powder. Mp \> 260°C. ^1^H NMR (300 MHz, DMSO-*d*~6~) δ (ppm) = 3.34 (br s, 8H, N(CH~2~)~4~N), 7.28--7.7 (m, 12H, H-2', H-3', H-4', Ar, =CH). ^13^C NMR (75 MHz, DMSO-*d*~6~) δ (ppm) = 42.45 (N(CH~2~)~4~N), 129.08 (C-2'), 129.16 (=CH), 129.22 (C=), 129.55 (C-3'), 129.82 (C-4'), 129.94 (C-1'); 130.41 (C=N), 159.56 (C=O). HRMS, *m/z* = 483.0918 found (calculated for C~24~H~20~N~4~O~2~NaS~2~, \[M+Na\]^+^ requires 483.0925). Anal. Calcd. for C~24~H~20~N~4~O~2~S~2~: C, 62.59; H, 4.38. Found: C, 62.56; H, 4.41.

(5Z,5'Z)-2,2'-(Piperazine-1,4-diyl)bis\[5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one\] (1,4-Bis\[(5Z)-5-(4-methoxybenzylidene)-4-oxo-4,5-dihydro-1,3-thiazol-2-yl\]piperazine, 5b)
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Prepared following General procedure III from 5-(4-methoxybenzylidene)-2-thioxothiazolidin-4-one (**3b**) (1.005 g, 4 mmol) and piperazine **4a** (172 mg, 2 mmol) at 80°C to give **5b** in 36% yield as a yellow powder. Mp \> 260°C. ^1^H NMR (300 MHz, DMSO-*d*~6~) δ (ppm) = 2.99 (s, 8H, N(CH~2~)~4~N), 3.79 (s, 6H, OCH~3~), 7.04 (d, J = 5 Hz, 4H, H-3', Ar), 7.16 (s, 2H, =CH), 7.43 (d, J = 8.7 Hz, 4H, H-2', Ar). ^13^C NMR (75 MHz, DMSO-*d*~6~) δ (ppm) = 42.99 (N(CH~2~)~4~N), 55.27 (OCH~3~), 114.54 (C-3'), 114.73 (C-1'), 124.13 (=CH), 127.55 (C=, C-5), 131.29 (C-2'), 131.38 (C-4'), 132.14 (C=N, C-2), 159.56 (C=O, C-4). HRMS, *m/z* = 521.1317 found (calculated for C~26~H~25~N~4~O~4~S~2~, \[M+H\]^+^ requires 521.1310). Anal. Calcd. for C~26~H~24~N~4~O~4~S~2~: C, 59.98; H, 4.65. Found: C, 59.87; H, 4.64.

(5Z,5'Z)-2,2'-(Piperazine-1,4-diyl)bis\[5-(1,3-benzodioxol-5-ylmethylene)-1,3-thiazol-4(5H)-one\] (1,4-Bis\[(5Z)-5-(1,3-benzodioxol-5-ylmethylene)-4-oxo-4,5-dihydro-1,3-thiazol-2-yl\]piperazine, 5c)
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Prepared following General procedure III from 5-(1,3-benzodioxol-5-ylmethylidene)-2-thioxothiazolidin-4-one (**3c**) (1.061 g, 4 mmol) and piperazine **4a** (172 mg, 2 mmol) in hexane (2 ml) at 120°C to give **5a** in 15% yield as a brown powder. Mp \> 260°C. ^1^H NMR (300 MHz, DMSO-*d*~6~) δ (ppm) = 3.02 (s, 8H, N(CH~2~)~4~N), 6.11 (s, 4H, OCH~2~O), 7.02--7.18 (m, 6H, H-2', H-5', H-6', Ar), 7.58 (s, 2H, =CH). ^13^C NMR (75 MHz, DMSO-*d*~6~) δ (ppm) = 52.72 (N(CH~2~)~4~N), 101.88 (OCH~2~O), 108.71 (C-2'), 125.13 (C-5'), 126.04 (C=, C-5), 127.86 (C-1'), 130.41 (C-6'), 144.21 (=CH), 146.02 (C=N, C-2), 148.11 (C-4'), 148.78 (C-3'), 182.22 (C=O, C-4). HRMS, *m/z* = 571.0726 found (calculated for C~26~H~20~N~4~O~6~NaS~2~, \[M+Na\]^+^ requires 571.0722). Anal. Calcd. for C~26~H~20~N~4~O~6~S~2~: C, 56.92; H, 3.67. Found: C, 56.96; H, 3.71.

(5Z,5'Z)-2,2'-\[Piperazine-1,4-diylbis(propane-3,1-diylimino)\]bis\[5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one\] (1,4-Bis(3-{\[(5Z)-5-(4-methoxybenzylidene)-4-oxo-4,5-dihydro-1,3-thiazol-2-yl\]amino}propyl)piperazine, 5d)
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Prepared following General procedure III from 5-(4-methoxybenzylidene)-2-thioxothiazolidin-4-one (**3b**) (1.005 g, 4 mmol) and 1,4-bis(3-aminopropyl)piperazine (**4b**) (0.4 g, 2 mmol) in hexane (2 ml) at 120°C to give **5d** in 25% yield as a yellow powder. Mp = 220--222°C. 1H NMR (300 MHz, DMSO-*d*~6~) δ (ppm) = 1.68 (quint, J = 6.9 Hz, 4H, NCH~2~C[H]{.ul}~2~CH~2~N(CH~2~)~4~N), 2.37 (t, J = 6.7 Hz; 4H, NCH~2~CH~2~C[H]{.ul}~2~N(CH~2~)~4~N), 2.57 (s, 8H, NCH~2~CH~2~CH~2~N(C[H]{.ul}~2~)~4~N), 2.84 (t, J = 7.1 Hz, 4H; NC[H]{.ul}~2~CH~2~CH~2~N(CH~2~)~4~N), 3.79 (s, 6H, OCH~3~), 7.02 (d, J = 8.8 Hz, 4H, H-3', Ar), 7.18 (s, 2H; =CH), 7.44 (d, J = 8.8 Hz, 4H, H-2', Ar). ^13^C NMR (75 MHz, DMSO-*d*~6~) δ (ppm) = 23.39 (NCH~2~[C]{.ul}H~2~CH~2~N(CH~2~)~4~N), 37.41 (N[C]{.ul}H~2~CH~2~CH~2~N(CH~2~)~4~N), 52.03 (NCH~2~CH~2~CH~2~N([C]{.ul}H~2~)~4~N), 54.42 (NCH~2~CH~2~[C]{.ul}H~2~N(CH~2~)~4~N), 55.27 (OCH~3~), 114.58 (C-3'), 125.04 (=CH), 127.28 (C-1'), 130.99 (C=), 131.44 (C-2'), 159.77 (C-4'), 201.61 (C=N, C-2), 206.74 (C=O, C-4). HRMS, *m/z* = 635.2396 found (calculated for C~32~H~39~N~6~O~4~S~2~, \[M+H\]^+^ requires 635.1819). Anal. Calcd. for C~32~H~38~N~6~O~4~S~2~: C, 60.54; H, 6.03. Found: C, 60.57; H, 6.07.

(5Z,5'Z)-2,2'-\[Piperazine-1,4-diylbis(propane-3,1-diylimino)\]bis\[5-(1,3-benzodioxol-5-ylmethylene)-1,3-thiazol-4(5H)-one\] (1,4-Bis(3-{\[(5Z)-5-(1,3-benzodioxol-5-ylmethylene)-4-oxo-4,5-dihydro-1,3-thiazol-2-yl\]amino}propyl)piperazine, 5e)
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Prepared following General procedure III from 5-(1,3-benzodioxol-5-ylmethylidene)-2-thioxothiazolidin-4-one (**3c**) (1.061 g, 4 mmol) and 1,4-bis(3-aminopropyl)piperazine (**4b**) (0.4 g, 2 mmol) in hexane (2 ml) at 120°C to give **5e** in 15% yield as a brown powder. Mp = 222--224°C. ^1^H NMR (300 MHz, DMSO-*d*~6~) δ (ppm) = 1,69 (quint, J = 6.9 Hz, 4H, NCH~2~C[H]{.ul}~2~CH~2~N(CH~2~)~4~N), 2.37 (t, J = 6.6 Hz, 4H, NCH~2~CH~2~C[H]{.ul}~2~N(CH~2~)~4~N), 2.37 (s, 8H, NCH~2~CH~2~CH~2~N(C[H]{.ul}~2~)~4~N), 2.83 (t, J = 7.1 Hz, 4H, NC[H]{.ul}~2~CH~2~CH~2~N(CH~2~)~4~N), 6.07 (s, 4H, OCH~2~O), 7.02 (m, 6H, H-2', H-5', H-6', Ar), 7.14 (s, 2H, =CH). ^13^C NMR (75 MHz, DMSO-*d*~6~) δ (ppm) = 23.47 (NCH~2~[C]{.ul}H~2~CH~2~N(CH~2~)~4~N), 37.45 (N[C]{.ul}H~2~CH~2~CH~2~N(CH~2~)~4~N), 52.22 (NCH~2~CH~2~CH~2~N([C]{.ul}H~2~)~4~N), 54.54 (NCH~2~CH~2~[C]{.ul}H~2~N(CH~2~)~4~N), 101.52 (OCH~2~O), 108.74 (C-2'), 108.82 (C-5'), 124.21 (C-6'), 124.84 (=CH), 147.72 (C-4'), 147.89 (C-3'), 182.66 (C=, C-5), 202.14 (C=N, C-2), 206.72 (C=O, C-4). HRMS, *m/z* = 663.1981 found (calculated for C~32~H~35~N~6~O~6~S~2~, \[M+H\]^+^ requires 663.7790). Anal. Calcd. for C~32~H~34~N~6~O~6~S~2~: C, 57.99; H, 5.17. Found: C, 57.92; H, 5.16.

In vitro kinase inhibition assays
---------------------------------

*Buffer A*: 10 mM MgCl~2~, 1 mM EGTA, 1 mM DTT, 25 mM Tris-HCl pH 7.5, 50 μg heparin/ml. *Buffer C*: 60 mM ß-glycerophosphate, 15 mM *p*-nitrophenylphosphate, 25 mM Mops (pH 7.2), 5 mM EGTA, 15 mM MgCl~2~, 1 mM DTT, 1 mM sodium vanadate, 1 mM phenylphosphate. Kinase activities were assayed in Buffer A or C, at 30°C, at a final ATP concentration of 15 μM. Blank values were subtracted and activities expressed in % of the maximal activity, i.e. in the absence of inhibitors. Controls were performed with appropriate dilutions of DMSO. The kinase peptide substrates were obtained from Millegen (Labege, France). *DYRK1A* and *DYRK2* (human, recombinant, expressed in *E. coli* as a GST fusion protein) were purified by affinity chromatography on glutathione-agarose and assayed in buffer A (+ 0.5 mg BSA /ml) using Woodtide (KKISGRLSPIMTEQ) (1.5 µg/assay) as a substrate, in the presence of 15 µM \[γ-^33^P\] ATP (3,000 Ci/mmol; 10 mCi/ml) in a final volume of 30 μl. After 30 min incubation at 30°C, the reaction was stopped by harvesting onto P81 phosphocellulose papers (Whatman) using a FilterMate harvester (Packard) and were washed in 1% phosphoric acid. Scintillation fluid was added and the radioactivity was measured in a Packard counter. *CLK1* and *CLK3* (human, recombinant, expressed in *E. coli* as GST fusion proteins) were assayed in buffer A (+ 0.15 mg BSA /ml) with RS peptide (GRSRSRSRSRSR) (1μg/assay). *CDK5/p25* (human, recombinant) was prepared as previously described \[26\]. Its kinase activity was assayed in buffer C, with 1 μg histone H1 /ml. *GSK-3α/β* (porcine brain, native) was assayed in Buffer A and using a GSK-3 specific substrate (GS-1: YRRAAVPPSPSLSRHSSPHQSpEDEEE) (pS stands for phosphorylated serine) \[[@b20-scipharm.2012.80.825]\].

Cell culture and survival assays
--------------------------------

Skin diploid fibroblastic cells were provided by BIOPREDIC International Company (Rennes, France). Caco-2 cells and Huh7 cells were obtained from the ECAC collection. Cells were grown according to ECAC recommendations. The RLEC-F1 clone was derived from an established rat biliary epithelial cell line as previously described \[[@b21-scipharm.2012.80.825]\]. The toxicity test of the compounds on these cells was as follows: 4 × 10^3^ cells were seeded in 96 multiwell plates and left for 24 h for attachment, spreading, and growing. Then they were exposed for 48 h to increasing concentrations of the compounds, ranging from 0.1 to 25 μL in a final volume of 80 μL of culture medium. They were then fixed with 4% paraform-aldehyde solution and the nuclei were stained with Hoechst 3342 and counted using automated imaging analysis (Simple PCI software).
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![Structures of Darbufelone (**A**), DBPT (**B**), inhibitor of DSP (**C**), and epalrestat (**D**).](scipharm-2012-80-825f1){#f1-scipharm.2012.80.825}

![a) for **3a--c**: MeOH, AcONa 3 eq., MWI, 65°C, 10 min. and for **3d--g**: MWI, 130°C, 10 min. b) MWI, 80--120°C, 30 min.](scipharm-2012-80-825f2){#f2-scipharm.2012.80.825}

###### 

Cell effects of the products and calculated partition coefficients log P (calculated with Chem Draw Pro, Cambridge Soft)

  **Cpd.**      **Cell lines IC~50~ (μM)**                                                   
  ------------- ---------------------------- ------- ------- ------- ------- ------- ------- -----
  **3a**        \> 25                        \> 25   \> 25   \> 25   \> 25   \> 25   \> 25   2.0
  **3b**        \> 25                        \> 25   \> 25   \> 25   \> 25   \> 25   \> 25   1.9
  **3c**        \> 25                        \> 25   \> 25   \> 25   \> 25   \> 25   \> 25   1.8
  **5a**        \> 25                        25      \> 25   \> 25   \> 25   \> 25   \> 25   4.8
  **5c**        \> 25                        20      \> 25   \> 25   40      \> 25   40      5.3
  Roscovitine   10                           10      15      8       8       20      \> 25   --
  DMSO          \> 25                        \> 25   \> 25   \> 25   \> 25   \> 25   \> 25   --

###### 

CDK5/p25, GSK3α/β, DYRK1A, DYRK2, CLK1, CLK3 inhibitions.

  **Cpd.**   **IC~50~ (μM)**                                   
  ---------- ----------------- ------- ------- ------- ------- -------
  **3a**     \> 10             \> 10   \> 10   \> 10   \> 10   \> 10
  **3b**     \> 10             \> 10   \> 10   \> 10   \> 10   \> 10
  **3c**     \> 10             8.5     0.070   --      --      --
  **5d**     \> 10             \> 10   0.041   0.6     0.5     7.7
